Company
Consulting firm that produced an independent report on Breakthrough Victoria's portfolio impact
Every investor coverage indicates participated in a round EY-Parthenon raised.
Companies EY-Parthenon acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming EY-Parthenon. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Breakthrough Victoria announces a $1 million investment in AlleSense, a La Trobe University spin-out developing nanofabricated slides for faster cancer diagnosis, joining round leader Welcome Ventures.
Breakthrough Victoria is putting $75 million into five venture capital funds, including Virescent, SYNthesis BioVentures, Scale and Galileo, each of which has pledged a quarter of its capital to Victorian startups.
Breakthrough Victoria announces the first three fellows of its $7.5 million fellowship, giving each researcher $150,000 and support to turn research into startups in mental health games, IVF imaging and skin cancer detection.
Breakthrough Victoria reflects on its 2022 investment in quantum company Infleqtion, part of a larger raise, detailing Victorian operations, university partnerships, workforce programs and a planned US listing via SPAC.